Recent Updates
Recently added Catalysts
SMMT Positive Sentiment

Ivonescimab Data Sets across Multiple Tumor Types to Be Featured at ESMO 2026

Thursday, October 22, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Summit Therapeutics announced that ivonescimab data will be presented at ESMO 2026. The presentations will cover various tumor types, highlighting positive overall survival results from Akeso Inc.'s Phase III HARMONi-GI1 study. The event is scheduled for October 23-27, 2026, in Madrid, Spain.

Market Sentiment Analysis

POSITIVE FACTORS

  • Ivonescimab data shows positive overall survival findings.
  • Multiple presentations planned at ESMO 2026.
  • Broad range of tumor types will be covered.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+48%
120-day peak, hindsight
Typical move
39.8%
average across 4 past catalysts
Cash runway
~12 mo
Low dilution risk
Lead asset
Ivonescimab
NDA/BLA · Non-Squamous Non-small Cell Lung Cancer

Full Press Release Details

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that ivonescimab data will be featured in numerous presentations at the European Society for Medical Oncology 2026 Congress (ESMO 2026), taking place October 23-27, 2026, in Madrid, Spain. Across 10 presentations at ESMO 2026, ivonescimab data will span a broad range of tumor types, led by positive overall survival findings from Akeso Inc.’s Phase III HARMONi-GI1 study of ivonescimab plus chemotherapy compared to du

Frequently Asked Questions

What is ivonescimab?

Ivonescimab is a therapeutic agent being studied for various tumor types.

When is ESMO 2026 taking place?

ESMO 2026 will be held from October 23-27, 2026.

What were the findings from the HARMONi-GI1 study?

The study reported positive overall survival findings for ivonescimab.

Where will ESMO 2026 be held?

The congress will take place in Madrid, Spain.

ShareAdd on Google
Tags: SMMT Summit Therapeutics ivonescimab ESMO 2026 Akeso Inc. Phase III
Last updated: Oct 22, 2026

Biotech snapshot

Cash runway
$691M liquidity · $47M/mo burn
~12 mo
Low dilution risk
Lead asset
IvonescimabNDA/BLA
Non-Squamous Non-small Cell Lung Cancer →

Catalyst track record

+48%
best trade around SMMT's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for SMMT.

See every catalyst's timing & PoA →